Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

Telix Pharmaceuticals Announces Results of Successful SPP

ASX, News,

Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6…

Read more

Telix Pharmaceuticals to Present at Jefferies Healthcare Conference

Events, News,

Telix Pharmaceuticals is pleased to announce Telix’s CEO, Dr. Christian Behrenbruch will present at the Jefferies Healthcare Conference at the Grand Hyatt Hotel in New York at 8:00 AM EDT…

Read more

Telix Pharmaceuticals Annual Report 2018

ASX, News,

Telix Pharmaceuticals Limited is pleased to provide its Annual Report…

Read more

Telix Pharmaceuticals launches information site on illumet™ prostate cancer imaging product

Clinical, News,

Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical…

Read more

Strategy Update – Acceleration of Prostate Cancer Therapy Program

Clinical, News,

Telix Pharmaceuticals Limited today announced a strategy update for the TLX591 (prostate therapy)…

Read more

Telix Pharmaceuticals Ltd Detailed Program Update January 2019

ASX, News,

Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January…

Read more

Telix Pharmaceuticals & Radboud University Medical Centre Conclude Clinical Collaboration Agreement

Clinical, News,

Telix Pharmaceuticals has today announced a clinical collaboration with Radboud University Medical…

Read more

BioSpectrum Asia Interview with Dr Nishimura on APAC Oncology Market

News,

Telix is pleased to provide details of BioSpectrum Asia interview with Telix Japan President & COO Dr Shintaro Nishimura on the APAC oncology market & opportunities/challenges in the Japanese market…

Read more

Odile Jaume to Lead Telix’s European Operations

News,

Telix Pharmaceuticals Limited is delighted to announce the appointment of Ms. Odile Jaume as President and Chief Operating Officer (COO) of Telix’s European…

Read more

Telix Pharmaceuticals Establishes Japanese Subsidiary, Appoints Key Executives

News,

Telix Pharmaceuticals Limited is pleased to announce the establishment Telix Pharmaceuticals (Japan) Ltd and appointment of the first two members of the Japanese leadership…

Read more
1 … 42 43 44 45 46

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings